Generic Drug User Fees To Be Reconsidered By GPhA
This article was originally published in The Pink Sheet Daily
Executive Summary
GPhA CEO Jaeger tells House Energy & Commerce/Health Subcommittee that in the past user fees for ANDA reviews “didn’t make much sense” because of brand name drug manufacturer tactics for blocking generic approvals. The association will take another look at user fees and inform the committee of its decision.